Phosphoproteomic dysregulation drives tumor proliferation in Cushing's disease
David T. Asuzu, Dhruval Bhatt, Dustin Mullaney…·Prashant Chittiboina
This study identifies phosphoproteomic dysregulation as a driver of tumor proliferation in Cushing's disease and demonstrates reversibility using an FDA-approved PP2A agonist.